Overexpression of SphKs, S1P and the S1PRs are causally associated with cancer drug resistance to conventional cancer treatments (radiotherapy, chemo- and hormone therapies) in many types of cancers, including breast [92, 230], pancreatic [265], and prostate cancers [266]. This evidence concerns the gene MBTPS1 and prostate carcinoma.